We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

74 hedge funds and large institutions have $31M invested in Cue Biopharma in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more call options, than puts

Call options by funds: $292K | Put options by funds: $88K

0.1% more ownership

Funds ownership: 1.11% → 1.21% (+0.1%)

8% less funds holding

Funds holding: 80 → 74 (-6)

22% less capital invested

Capital invested by funds: $39.7M → $31M (-$8.76M)

33% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 27

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
74
Holders Change
-6
Holders Change %
-7.5%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
18
Reduced
27
Closed
10
Calls
$292K
Puts
$88K
Net Calls
+$204K
Net Calls Change
-$460K

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$2.35M
2
GCP
GSA Capital Partners
United Kingdom
+$459K
3
Renaissance Technologies
Renaissance Technologies
New York
+$439K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$354K
5
SPC
Sigma Planning Corp
Michigan
+$346K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$422K
2
CC
Carlson Capital
Texas
-$235K
3
BlackRock
BlackRock
New York
-$223K
4
AC
Annandale Capital
Texas
-$172K
5
Jane Street
Jane Street
New York
-$144K
Name Holding Trade Value Shares
Change 		Change in
Stake
BL
1
Bleichroeder LP
New York
$5.21M +$2.35M +33,333 +57%
SPC
2
Slate Path Capital
New York
$4.54M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.32M +$354K +5,015 +7%
BlackRock
4
BlackRock
New York
$4.24M -$223K -3,156 -4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.59M +$59.3K +841 +3%
State Street
6
State Street
Massachusetts
$1.44M +$179K +2,537 +11%
RSWM
7
Robertson Stephens Wealth Management
California
$904K – – –
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$815K -$62.7K -889 -6%
Northern Trust
9
Northern Trust
Illinois
$690K -$38K -539 -4%
Millennium Management
10
Millennium Management
New York
$684K +$203K +2,882 +31%
MAM
11
Monaco Asset Management
Monaco
$633K -$17.6K -250 -2%
Renaissance Technologies
12
Renaissance Technologies
New York
$518K +$439K +6,227 +214%
AR
13
Advisory Research
Illinois
$486K – – –
SPC
14
Sigma Planning Corp
Michigan
$484K +$346K +4,905 +135%
Bank of America
15
Bank of America
North Carolina
$460K -$53.1K -753 -8%
GCP
16
GSA Capital Partners
United Kingdom
$395K +$459K +6,505 +1,399%
Stifel Financial
17
Stifel Financial
Missouri
$364K -$3.25K -46 -0.7%
Morgan Stanley
18
Morgan Stanley
New York
$283K -$422K -5,984 -54%
N
19
Nuveen
North Carolina
$277K -$106K -1,507 -24%
Citadel Advisors
20
Citadel Advisors
Florida
$276K +$224K +3,181 +188%
Squarepoint
21
Squarepoint
New York
$220K +$171K +2,418 +166%
GLA
22
Good Life Advisors
Pennsylvania
$189K – – –
UBS Group
23
UBS Group
Switzerland
$176K -$14.8K -210 -6%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$174K -$40.3K -571 -16%
Charles Schwab
25
Charles Schwab
California
$173K -$33.3K -472 -13%
1
2 3 4

CUE Hedge Fund Activity: Q1 2024 in Review

74 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2024, worth a combined $31M — down 22% from $39.7M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CUE and 4 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 18 added.

The largest buyer was Bleichroeder LP, adding an estimated $2.35M. The largest seller was Morgan Stanley, cutting an estimated $422K.

  • 74 institutional investors held Cue Biopharma (CUE) as of Q1 2024, down from 80 in Q4 2023.
  • Funds reported $31M of Cue Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
  • 4 funds opened new Cue Biopharma positions in Q1 2024 and 10 closed out, a net change of -6 holders.
  • The largest Cue Biopharma buyer in Q1 2024 was Bleichroeder LP, an estimated $2.35M added.
  • The largest Cue Biopharma seller in Q1 2024 was Morgan Stanley, an estimated $422K sold.

Based on aggregated 13F filings for Q1 2024.